给感兴趣的人了解一下：
到2017年止， 光光是治疗疱疹的药物市场销售额将达到48亿美金。 多么庞大的数字， 一定是感染的人数大幅上升， 才会导致如此巨大的数额预测。
其实是个不太好的消息。 意味着如果一旦治愈的药物一出， 那么这些治疗的药物都得淘汰， 意味着如果治愈， 越来越少的人使用药物， 将会造成这些大的制药厂不盈利， 全球主要制药工业的盈利下降， 特别是美国。 这个问题是否是导致许多工业巨头阻止治愈药物的研发和上市， 或者买断科学家的研究， 不让他们继续参与， 比如哈佛大学可耐普教授的专利被买断然后被踢出去？？ 我的怀疑？？ 对这些资本家来说 治愈意味着他们的亏损， 所以他们特别害怕治愈的事情出现， 与我们的愿望背道而驰！！
下段文章摘自美国全球工业分析的行业研究报告。 还提到一种新药治疗药比 valtrex 要好， 叫做 nanoviricides。 我本人没有听说过这个药名， 我将去问问国外的医生此药的情况？？ 还真是第一次听说这个药名。 Nanoviricides, 大家也可以去打听一下。 下边的一段说这个药比valtrex 就是盐酸伐西罗伟好。
还有一个假设， 他们期限定在2017年 我有一个假设， 是否他们预料到差不多2017年前治愈的药也就差不多推出了？？？ 为什么不做个十年预测到 2020年 或者 2019， 选择2017年， 我的推测是差不多在2017年前， 治愈的药肯定有了。 我的推测， 仅是自己的猜测！！ 我再次与cullen在2008年说的一句话联系起来， 他那是说 2008年说的， 不出十年治愈一定发生， 那就是 2018年之前， 所以我想领域研究报告定在2017年绝对可能预测到那时解药就有了。 不知我的推测有否理论根据？？？？
迷糊
Press Releases.Global Herpes Simplex Virus Treatment Market to Reach $4.8 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.
Read more:
http://www.sfgate.com/cgi-bin/article.cgi?f=/g/a/2011/04/04/prweb8257847.DTL#ixzz1JtFkcstOThe HSV therapeutic market comprises drugs that are used for treating outbreaks and symptoms of herpes. These include drugs such as Acyclovir and valacyclovir, sold under Zovirax and Valtrex brands by GlaxoSmithKline. Acyclovir and valacyclovir are also available in generic variants, as the respective original drugs lost their patent protection. Promising drugs in the area of HSV treatment include Nanoviricides. These drugs have a distinct action mechanism when compared to existing drugs, which bodes the emergence of a potentially robust drug for treating HSV.
The US represents the largest regional market for Herpes Simplex Virus treatment worldwide, as stated by the new market research report on Herpes Simplex Virus Treatment. However, growth in the market would be led by US, which is projected to be the fastest growing regional market during the analysis period. Rest of World is projected to post a compounded annual growth rate of close to 6.9% during the analysis period.
Major players profiled in the report include Agenus Inc., AiCuris GmbH & Co.KG, Astellas Pharma Inc., BioVex, Clinigen Group, Cytogenix Inc., GlaxoSmithKline Plc., Lumavita AG, NanoBio Corporation, NanoViricides Inc., Novartis International AG, Sanofi-Aventis, Sinclair Pharma Plc., Starpharma Holdings Limited, Vical, Genocea Biosciences, among others.
The research report titled "Herpes Simplex Virus Treatment: A Global Strategic Business Report" announced by Global Industry Analysts Inc., provides a comprehensive review of the Herpes Simplex Virus treatment, current market trends, key growth drivers, the available treatment, overview of major drugs, insight into current leading and pipeline drugs, recent product approvals, recent industry activity, and profiles of major/niche global as well as regional market participants. The report provides annual sales estimates and projections for Herpes Simplex Virus treatment for the years 2009 through 2017 for the following geographic markets - US, Europe, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.
